Lombardi Cancer Center study suggests resistance to lung cancer targeted therapy can be reversed
- Posted: June 11, 2014
Scientists at Georgetown Lombardi Comprehensive Cancer Center and the National Cancer Institute have discovered why intrinsic resistance occurs to lung cancer targeted therapy -- and they pinpoint a drug they say could potentially reverse it. Their findings, published in the Journal of Clinical Investigation.
Among the research institutions NCI funds across the United States, it currently designates 68 as Cancer Centers. Largely based in research universities, these facilities are home to many of the NCI-supported scientists who conduct a wide range of intense, laboratory research into cancer’s origins and development. The Cancer Centers Program also focuses on trans-disciplinary research, including population science and clinical research. The centers’ research results are often at the forefront of studies in the cancer field.